TrialThe lancet. Diabetes & endocrinology2020

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.

David Z I Cherney et al.PubMed ↗Publisher ↗

No numbers read from the abstract.